1, Via Matteo Civitali
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com
Settore/i: Healthcare
Settore: Drug Manufacturers—General
Impiegati a tempo pieno: 4.300
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Robert Koremans M.D. | CEO & Director | 135k | N/D | 1962 |
Ms. Cathrin Petty | Exec. Director | N/D | N/D | 1973 |
Mr. Giampiero Mazza | Exec. Director | N/D | N/D | 1969 |
Mr. Giorgio De Palma | Exec. Director | N/D | N/D | 1974 |
Mr. Luigi Felice La Corte | Group CFO & Exec. Director | N/D | N/D | 1969 |
Ms. Federica De Medici | Director of Investor Relations & Corp. Communications | N/D | N/D | N/D |
Ms. Daria Ghidoni | Group Gen. Counsel | N/D | N/D | N/D |
Mr. Giovanni Minora | Group Audit & Compliance | N/D | N/D | N/D |
Mr. Gabriele Finzi | Exec. VP of Corp. Devel. & Licensing | N/D | N/D | N/D |
Mr. Giuseppe Gualazzini | Sr. VP of Group HR | N/D | N/D | 1959 |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
L'ISS Governance QualityScore di Recordati Industria Chimica e Farmaceutica S.p.A. al 1 marzo 2023 è 2. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 3; retribuzione: 4.